Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
05 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/05/2974856/0/en/Erasca-to-Present-at-Upcoming-Investor-Conferences.html
24 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/10/24/2968636/0/en/Erasca-Announces-Strong-Momentum-for-Naporafenib-and-RAS-Targeting-Franchise.html
25 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/25/2952906/0/en/Erasca-to-Present-Preliminary-SEACRAFT-1-Phase-1-Data-for-Naporafenib-Plus-Trametinib-in-RAS-Q61X-Mutant-Solid-Tumors-as-Oral-Presentation-at-36th-EORTC-NCI-AACR-Symposium.html
29 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/29/2937732/0/en/Erasca-to-Present-at-Upcoming-Investor-Conferences-in-September.html
12 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/12/2928728/0/en/Erasca-Reports-Second-Quarter-2024-Business-Updates-and-Financial-Results.html
18 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/18/2900371/0/en/Erasca-Initiates-SEACRAFT-2-Pivotal-Phase-3-Trial-Evaluating-Naporafenib-Plus-Trametinib-in-Patients-with-NRAS-Mutant-Melanoma.html
Details:
ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2024
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Erasca Starts Phase 3 Trial for Naporafenib in Melanoma
Details : ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.
Brand Name : ERAS-254
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 18, 2024
Details:
The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $184.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 21, 2024
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $184.0 million
Deal Type : Public Offering
Erasca Announces Closing of Underwritten Offering of Common Stock and Additional Shares
Details : The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.
Brand Name : ERAS-254
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 21, 2024
Details:
Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Small molecule
Sponsor: BofA Securities
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 27, 2024
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : BofA Securities
Deal Size : $45.0 million
Deal Type : Private Placement
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Details : Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.
Brand Name : ERAS-254
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2024
Details:
The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 14, 2024
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Erasca Announces Clinical Trial Collaboration and Supply Agreements for Trametinib
Details : The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.
Brand Name : ERAS-254
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 14, 2024
Details:
LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .
Brand Name : ERAS-254
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Details:
ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Brand Name: ERAS-254
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Lead Product(s) : Naporafenib,Trametinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.
Brand Name : ERAS-254
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2023
Details:
ERAS-801 is a highly potent, selective, reversible, and orally available small molecule EGFR inhibitor with significantly enhanced CNS penetration. It is being developed for glioblastoma multiforme.
Lead Product(s): ERAS-801
Therapeutic Area: Oncology Brand Name: ERAS-801
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details : ERAS-801 is a highly potent, selective, reversible, and orally available small molecule EGFR inhibitor with significantly enhanced CNS penetration. It is being developed for glioblastoma multiforme.
Brand Name : ERAS-801
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2023
Details:
ERAS-007 is an oral ERK1/2 inhibitor. ERAS-007 + EC was generally well tolerated with mostly low-grade treatment-related adverse events (TRAEs) at all combination doses tested for the treatment of metastatic BRAF V600E- colorectal cancer.
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Brand Name: ERAS-007
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Lead Product(s) : ERAS-007,Encorafenib,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
Details : ERAS-007 is an oral ERK1/2 inhibitor. ERAS-007 + EC was generally well tolerated with mostly low-grade treatment-related adverse events (TRAEs) at all combination doses tested for the treatment of metastatic BRAF V600E- colorectal cancer.
Brand Name : ERAS-007
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2023
Details:
ERAS-801 is a highly potent, selective, reversible, and orally available small molecule EGFR inhibitor with significantly enhanced CNS penetration. It is being developed for glioblastoma multiforme.
Lead Product(s): ERAS-801
Therapeutic Area: Oncology Brand Name: ERAS-801
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details : ERAS-801 is a highly potent, selective, reversible, and orally available small molecule EGFR inhibitor with significantly enhanced CNS penetration. It is being developed for glioblastoma multiforme.
Brand Name : ERAS-801
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 01, 2023
Details:
ERAS-007 is a potential best-in-class ERK1/2 inhibitor being investigated alone or in combination with different inhibitors targeting upstream nodes of the RAS/MAPK pathway as part of Erasca’s MAPKlamp strategy.
Lead Product(s): ERAS-007,ERAS-601
Therapeutic Area: Oncology Brand Name: ERAS-007
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Lead Product(s) : ERAS-007,ERAS-601
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ERAS-007 is a potential best-in-class ERK1/2 inhibitor being investigated alone or in combination with different inhibitors targeting upstream nodes of the RAS/MAPK pathway as part of Erasca’s MAPKlamp strategy.
Brand Name : ERAS-007
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 20, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?